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Цель. Оценить эффективность применения аминокапроновой кислоты для снижения периопераци-
онной кровопотери при первичном тотальном протезировании коленного сустава. 
Материал и методы. В исследование включено 82 пациента, которым было выполнено тотальное 
протезирование коленного сустава. В исследуемой группе (42 пациента) применяли парентеральное вве-
дение аминокапроновой кислоты (5% раствор) в дозировке 100 мг/кг до наложения жгута, с повторным 
введением рассчитанной дозы препарата через 4 часа. Пациентам контрольной группы (40 человек) не 
проводилось введение аминокапроновой кислоты. В группах проводили сравнительную оценку следующих 
показателей: концентрации гемоглобина, количеста эритроцитов, гематокритного объема эритроцитов до 
операции и в послеоперационном периоде (5 сутки). Выполняли учет величины кровопотери по дренажу в 
течение 24 часов после операции.
Результаты. Выявлено значительное сокращение объема кровопотери по дренажу в исследуемой 
группе  (300; 200-350 мл (Me; 25%; 75%)) по сравнению с контрольной (600; 525-725 мл (Me; 25%; 75%)), 
p<0,001. Среднее значение показателей крови в послеоперационном периоде в исследуемой группе (гемо-
глобин 118; 105-124 г/л, эритроциты 3,95; 3,7-4,2×1012/л, гематокрит 36,55; 32,8-39,6 (Me; 25%; 75%)) было 
достоверно выше, чем в группе контроля (гемоглобин 105,5; 95-119 г/л, эритроциты 3,45; 3,1-3,9×1012/л, 
гематокрит 30,95; 29,65-34,05 (Me; 25%; 75%)), p<0,05. В контрольной группе 11 пациентам (27,5%) прово-
дилось переливание эритроцитной массы. Переливания компонентов донорской крови пациентам исследу-
емой группы не проводили. Не было каких-либо осложнений, связанных с применением аминокапроновой 
кислоты. 
Заключение. Применение аминокапроновой кислоты позволяет повысить эффективность лечения 
пациентов с дегенеративно-дистрофическими заболеваниями коленного сустава за счет исключения необ-
ходимости переливания донорской крови при тотальном эндопротезировании коленного сустава, а также 
снижения экономических затрат на обеспечение данного оперативного вмешательства.
Ключевые слова: протезирование коленного сустава, кровопотеря, ингибиторы фибринолиза, аминока-
проновая кислота, гемотрансфузия, экономическая эффективность, оперативное вмешательство
Objectives. To evaluate the effectiveness of aminocaproic acid for reducing the perioperative blood  loss in 
primary total knee joint replacement.
Methods. The patients (n=82) with the total knee joint replacement were included in the study. In the study 
group (n=42) parenteral administration of aminocaproic acid (100 mg/kg, 5% solution) was administered before 
applying the tourniquet, with repeated administration of the calculated dose of the drug in 4 hours. Patients of the 
control group (n=40) did not receive aminocaproic acid. The following indicators were compared: hemoglobin 
concentration, erythrocyte count, hematocrit volume of red blood cells prior to surgery and in the postoperative 
period (5 days). Drainage blood was recorded within 24 hours after the operation.
Results. In the study group  blood loss/drainage volume was significantly reduced (300, 200-350 ml (Me 25%, 
75%)) compared to the control group (600, 525-725 ml (Me, 25%, 75%)), p<0,001. In the postoperative period 
the drainage blood loss and calculated blood loss volumes were significantly higher for the control group (mean 
value of blood indicators in the study group: hemoglobin 118, 105 – 124 g/l, erythrocytes 3,95, 3,7 – 4,2×1012/l, 
hematocrit 36,55, 32,8 – 39,6 (Me 25%, 75%) and mean value of blood indicators: hemoglobin 105,5, 95 – 119 g/l, 
erythrocytes 3,45, 3,1 – 3,9×1012/ l, hematocrit 30, 95, 29,65 – 34,05 (Me, 25%, 75%)), p<0,05, respectively. In 
the control group, 11 patients (27,5%) were subjected to massive red blood cell transfusion. Donor blood component 
transfusion was not performed in the patients of the study group. No complication associated with aminocaproic 
acid application was registered.
Conclusion. The use of aminocaproic acid has proved to be an efficient and practical method of treatment 
patients with degenerative dystrophic diseases of the knee joint by eliminating the need for surgical blood transfusion 
in the total knee joint replacement, as well as by decreasing reimbursement for surgical procedures.
Keywords: knee joint replacement, blood loss, fibrinolysis inhibitors, aminocaproic acid, blood transfusion, 
economic costs, surgical intervention 
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Introduction 
Total knee joint replacement is one of the most 
effective and dynamically developing technologies 
of current orthopedics. In the whole world, includ-
ing the orthopedic clinics in Belarus, the incidence 
of arthroplasty operations performed annually has 
increased [1, 2].  However, the unsolved problems 
of this type of surgical interventions enable to  effect 
significantly on the outcomes of treatment remain. 
One of these unsolved problems is perioperative 
hemorrhage, the volume of which, according to 
various sources, can be up to 1500 ml. As a rule, 
endoprosthetics of the knee joint is performed using 
a pneumatic tourniquet, which minimizes the blood 
loss directly during the operation. But after removal 
of the tourniquet, diffuse bleeding from periarticu-
lar tissues intensifies due to reflex vasoplegia and 
activation of the fibrinolysis system. The total post-
operative volume of blood lost includes blood from 
drains as well as the "hidden" volume, represented by 
interstitial and intraarticular hematomas. [3, 4, 5].
 Significant blood loss accompanying such sur-
geries, leads to the development of post-operative 
anemia, increases the risk of infectious complica-
tions and duration of treatment in a hospital [6]. 
Donor red blood cell and plasma transfusions is 
most often used to treat and prevent the postop-
erative anemia. The average incidence rate of the 
postoperative blood transfusions is about 45% [7]. 
This method of blood loss compensation is expen-
sive, and is at risk of developing various (including 
severe) complications [8].  
Nowadays in the Republic of Belarus there is 
no single protocol for reducing the perioperative 
blood loss in the replacement of the knee joint. 
Known technologies and algorithms of blood saving 
are diverse, not standardized and differ significantly 
in orthopedic clinics [9].
One of the ways to prevent the perioperative 
blood loss is considered to be  used inhibitors of 
fibrinolysis. Their effectiveness, safety, significant 
reduction in economic costs in comparison with 
other methods is confirmed by many studies [10, 11]. 
Tranexamic acid is most often used in world clini-
cal practice. Many authors position this drug as the 
"strongest" inhibitor of fibrinolysis [3, 12, 13]. This 
group of drugs also includes aminocaproic acid, which 
is cheaper and more affordable, but, at the moment, 
unlike tranexamic acid has no wide application and 
evidence base for endoprosthetics of large joints [14].
Objectives. To evaluate the effectiveness of 
aminocaproic acid for reducing perioperative blood 
loss in primary total knee joint replacement.
Methods
A prospective open study of the patients (n=82) 
who underwent a primary unilateral total knee joint 
replacement for gonarthrosis, grade III  in the clinic 
of traumatology and orthopedics on the basis of 
Vitebsk Regional Clinical Hospital were enrolled. 
Prior to  operation the patients were informed in 
details and the protocol of voluntary consent for 
participation in this study was drawn up.
The criteria for inclusion in the study were: 
the age of patients (40-80 yrs), prior to operation 
hemoglobin values of less than 120 g/l (men) and 
110 g/l (women). The criteria for excluding patients 
from the study were: thrombosis (deep vein throm-
bophlebitis, thromboembolic syndrome, myocardial 
infarction), varicose veins of the lower limbs, ce-
rebral circulation disorders, coagulopathy, kidney 
disease with the impaired function, hypersensitivity 
to aminocaproic acid.
In accordance with the objectives of the study, 
as well as depending on the treatment performed, 
patients were divided into 2 groups. The groups 
were comparable in age, height, weight (Table 1).
The study group included patients who were 
parenterally administered aminocaproic acid (5% 
solution) at a dosage of 100 mg / kg before applying 
the tourniquet with repeated administration of the 
calculated dose of the drug after 4 hours. Patients of 
the control group did not receive aminocaproic acid.
All patients underwent a standard preoperative 
examination. In the case of necessity the consulta-
tions of such specialists as cardiologist, endocri-
nologist were appointed. Aspirin, non-steroidal 
anti-inflammatory drugs were abolished 3 days prior 
to the surgery. The majority of patients had con-
comitant pathology: arterial hypertension, ischemic 
heart disease, bronchial asthma, diabetes mellitus, 
alimentary obesity.
Table 1
Comparative characteristics of groups of patients (M±SD)
Note: *  – Student’s t-test; **  – criterion χ2.
Parameter Values of parameters in groups p
Study  group,  n=42 Control group,  n=40
Average age (years) 62,7±7,6 61,4±7,5 p>0,1*
Average height (cm) 165,2±8,6 164,1±9,7 p>0,1*
Average weight (kg) 86,6±12,1 82,1±12,2 p>0,1*
Number  of men/women 13/29 10/30 p>0,1**
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Spinal anaesthesia is considered to be the tech-
nique with an average volume of infusion therapy 
(1500 ml).  Surgical interventions were performed by 
one surgical team according to a standard technique 
with medial arthrotomy and using a pneumatic 
tourniquet. Bicondylar models of endoprostheses 
with preservation of the posterior cruciate ligament 
without replacing the articular patellar surface with 
rotational or fixed liners were used. The drainage 
was placed after inserting the components of the 
endoprosthesis, the wound was sutured layer by 
layer; the pressure bandage was applied. Draining 
of the operating wound was carried out within 24 
hours. Medication prophylaxis of thromboembolic 
complications was performed according to the cur-
rent clinical protocols for the treatment and preven-
tion of venous thromboembolism of the Ministry 
of Health of the Republic of Belarus. Mechanical 
prophylaxis was carried out by early mobilization of 
the patient, as well as the use of elastic bandage of 
the lower limbs in the postoperative period.
The following intergroup indicators were 
compared: hemoglobin concentration, erythrocyte 
count, hematocrit volume of erythrocytes prior to 
surgery and in the postoperative period (5 days). The 
blood counts were taken on the 5th day. According 
to the opinion of some authors by this time the 
volume of circulating blood had been recovered and 
the results obtained most accurately reflect the total 
blood loss in comparison with the baseline level. 
[15]. The total estimation of  blood loss/drainage 
volume occurred over 24 hours. The results were 
processed using Microsoft Office Excel 2010 and 
STATISTICA 10.0 package.
 The Shapiro-Wilk criterion was used for test-
ing hypotheses  regarding the distributional form. 
In the case of a normal distribution the Student’s 
t-test was used. In the distribution different from 
normal, the nonparametric methods were used 
and the Mann-Whitney test was used. The data of 
the studies are presented as mean value, standard 
deviation (M±SD) for values of signs subjected to 
normal distribution and median (Me), interquar-
tile interval [25%; 75%] for those, not subjected 
to normal distribution of values. For categorical 
data analysis the criterion ş2 was used. The level of 
statistical significance was assumed to be p<0,05.
Results
The account of intraoperative blood loss was not 
carried out since  in all cases blood volume was insig-
nificant due to a pneumatic tourniquet application. 
A significant decrease of this parameter in the 
study group was established by the comparative 
evaluation of the amount discharged by the drain-
age (Table 2).
The groups were statistically comparable ac-
cording to the initial data of hemoglobin concen-
tration, the number of erythrocytes and the hema-
tocrit volume of erythrocytes. When assessing the 
indicators of hemoglobin, erythrocyte, hematocrit, 
with subsequent comparison between the baseline 
values and obtained on the 5th day from the onset 
of surgical intervention, a reliable intergroup dif-
ference was revealed (Table 3).
When red blood cell transfusion was admin-
istered, not only the level of hemoglobin and the 
hematocrit volume of erythrocytes were taken into 
account, but also the presence of the circulatory 
disorders. A reduction of hemoglobin level of less 
than 80 g/l was considered to be an indication for 
blood transfusion. In patients with concomitant 
ischemic heart disease, a decrease of  hemoglobin 
concentration of less than 100 g/l was considered to 
be an indication for red blood cell transfusion. Based 
on this, 11 patients of the control group (27,5%) 
were transfused the erythrocyte mass (2 units). On 
Table 2
Comparative characteristics 
of groups of patients (M±SD)
Note: p  – Mann-Whitney test.
Note: p  – Mann-Whitney test.
Volume discharged by the drainage  (ml)
Study group,  n=42 Control group,  n=40 p
300  [200-350] 600  [525-725] p<0,001
Table 3
Comparative characteristics of indicators of hemoglobin concentration, the number of erythrocytes and 
the hematocrit volume of erythrocytes (Ме [25%; 75%])
Indicator Research group,  
n=42
Control group,  
n=40
p
Hemoglobin concentration before surgery (g/l) 142,5 [135-149] 142 [132,5-146] p=0,42
Hemoglobin concentration on the 5th day from the surgery (g/l) 118 [105-124] 105,5 [95-119] p<0,05
The number  of erythrocytes before surgery (1012/l) 4,75 [4,6-5,0] 4,8 [4,25-5,05] p=0,27
The number  of erythrocytes on the 5th day from the surgery 
(1012/l)
3,95 [3,7-4,2] 3,45 [3,1-3,9] p<0,05
The hematocrit volume of erythrocytes before surgery (%) 45,1 [41,0-46,9] 44,1 [38,95-45,75] p=0,1
The hematocrit volume of erythrocytes on the 5th day from the 
surgery (%)
36,55 [32,8-39,6] 30,95 [29,65-34,05] p<0,05
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the evening of surgery for total knee replacement 
only in 6 patients of the study group hemoglobin 
level  was less than 100 g/l, in 1 – less than 90 g/l. 
There was no need for allogeneic blood transfusion 
in the patients of the study group. 
Discussion
Prosthetics of large joints of the lower extrem-
ity may be accompanied by clinically significant 
blood loss. The results of the study demonstrate 
the effectiveness of using the fibrinolysis inhibitor 
(aminocaproic acid) in total knee joint replacement 
concordant with the data of a few pilot studies [14]. 
A significant reduction of  the amount of 
drainage content to be discharged in the case of 
using aminocaproic acid in recommended doses in 
comparison with control group was found out.The 
post-operative average volume of blood lost from 
drains in the control group (600 ml) was compa-
rable to those results of other clinical studies that 
performed similar measurements [4, 13, 15]. No 
drug -related complications had been documented, 
Also none of the patients had clinical signs of deep 
vein thrombosis and / or thromboembolic complica-
tions in the early postoperative period. Taking into 
account the age of patients and the concomitant 
pathology, minimization of blood loss has promoted 
early active rehabilitation, as well as the reduction 
in hospitalization terms of patients. 
A significant reduction of the postopera-
tive blood loss while using  aminocaproic acid 
is comparable to that of other similar studies in 
which tranexamic acid was used as the inhibitor 
of fibrinolysis [3, 6, 11, 13, 15]. The lower price 
of aminocaproic acid, as well as the presence of a 
domestic manufacturer, determines the rationality 
and prospects of using this drug.
Conclusions 
1. Aminocaproic acid has a pronounced blood-
saving effect in performing total knee replacements.
2. Parenteral administration of aminocaproic 
acid prior to operation is considered to be a safe 
method, permiting increase the effectiveness of 
treatment in patients with degenerative dystrophic 
diseases of the knee joint by eliminating the need 
for donor blood transfusion in the total knee re-
placement and also reducing the economic costs 
for providing this surgical intervention.
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